Volume 3, Issue 4 (12-2021)
alkhass 2021, 3(4): 6-10 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Nikaien D, Resalepour N, Rezaie S A. Another Perspective on Black Fungus Disease in Veterinary. alkhass 2021; 3 (4) :6-10
URL: http://alkhass.srpub.org/article-4-119-en.html
URL: http://alkhass.srpub.org/article-4-119-en.html
Department of Microbiology and Immunology, Faculty of Veterinary Medicine, University of Tehran, Iran
Abstract: (874 Views)
Mucormycosis, also known as black fungus is an opportunistic and serious fungal infection which is created by the order Mucorales. These fungi have a wide geographical distribution. The most important predisposing factors for this disease are hyperglycemia, metabolic acidosis, overuse of corticosteroids, neutropenia and blood malignancies. The disease occurs in several different forms; The most common of which is gastrointestinal and respiratory disorders in animals. Proper and timely diagnosis of the disease can play a key role in the prognosis, control and treatment of the disease. Since the disease can occur as a secondary infection in patients with COVID-19 who are being treated with corticosteroids to reduce inflammation, this study examines the status of black fungus disease in case reports of coronavirus in susceptible animals. Up to now, some cases of coronavirus and pneumoarthritis have been reported in animals.
Type of Study: Research |
Subject:
Veterinary Science
Received: 2021/10/15 | Revised: 2021/11/12 | Accepted: 2021/11/30 | Published: 2021/12/30
Received: 2021/10/15 | Revised: 2021/11/12 | Accepted: 2021/11/30 | Published: 2021/12/30
References
1. What is Mucormycosis? Severe fungal infection cases linked to COVID-19? https://timesofindia.indiatimes.com/life-style/healthfitness/health-news/coronavirus-severe-fungalinfection-cases-linked-to-covid-19-heres-what-weknow/photostory/79836584.cms?picid=79836589
2. Shikha G, Mucormycosis. A rare fungal infection linked to COVID-19: causes, symptoms, types, prevention, and treatment, 2020; https://www.jagranjosh.com/generalknowledge/mucormycosis-a-rare-fungal- infection1608646233-1
3. Zurl C, Hoenigl M, Schulz E. et al. Autopsy proven pulmonary mucormycosis due to Rhizopus microspores in a critically ill COVID-19 patient with underlying hematological malignancy. J Fungi. 2021; 7(2): 88. [DOI:10.3390/jof7020088] [PMID] [PMCID]
4. Gorbalenya AE. Severe acute respiratory syndrome-related coronavirus-The species and its viruses, a statement of the Coronavirus Study Group. BioRxiv. 2020. [DOI:10.1101/2020.02.07.937862]
5. Prabhu RM, Patel R. Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment. Clin Microbiol Infect. 2004; 10(suppl 1): 31-47. [DOI:10.1111/j.1470-9465.2004.00843.x] [PMID]
6. Waldorf AR. Pulmonary defense mechanisms against opportunistic fungal pathogens. Immunol Ser. 1989; 47: 271-342.
7. Chinn RY, Diamond RD. Generation of chemotactic factors by Rhizopus oryzae in the presence and absence of serum: relationship to hyphal damage mediated by human neutrophils and effects of hyperglycemia and ketoacidosis. Infect Immun. 1982; 38: 1123-1129. [DOI:10.1128/iai.38.3.1123-1129.1982] [PMID]
8. Boelaert JR, de Locht M, Van Cutsem J. et al. Mucormycosis during deferoxamine therapy is a siderophoremediated infection. In vitro and in vivo animal studies. J Clin Invest. 1993; 91: 1979-1986. [DOI:10.1172/JCI116419] [PMID] [PMCID]
9. Abe F, Inaba H, Katoh T, Hotchi M. Effects of iron and desferrioxamine on Rhizopus infection. Mycopathol. 1990; 110: 87-91. [DOI:10.1007/BF00446996] [PMID]
10. Artis WM, Fountain JA, Delcher HK, Jones HE. A mechanism of susceptibility to mucormycosis in diabetic ketoacidosis: transferrin and iron availability. Diabetes. 1982; 31: 1109-1114.
https://doi.org/10.2337/diabetes.31.12.1109 [DOI:10.2337/diacare.31.12.1109] [PMID]
11. Ibrahim AS, Spellberg B, Avanessian V, Fu Y, Edwards JE Jr. Rhizopus oryzae adheres to, is phagocytosed by, and damages endothelial cells in vitro. Infect Immun. 2005; 73: 778-783. [DOI:10.1128/IAI.73.2.778-783.2005] [PMID] [PMCID]
12. Jensen HE. Systemic bovine aspergillosis and zygomycosis in Denmark with reference to pathogenesis, pathology, and diagnosis. APMIS Suppl. 1994; 42: 1-48.
13. Jensen HE, Basse A, Aalbaek B. Mycosis in the stomach compartments of cattle. Acta Vet Scand. 1989; 30: 409-423. [PMC free article] [PubMed] [Google Scholar] [DOI:10.1186/BF03548017] [PMID] [PMCID]
14. Ortega J, Uzal FA, Walker R. et al. Zygomycotic lymphadenitis in slaughtered feedlot cattle. Vet Pathol. 2010; 47: 108-115. [DOI:10.1177/0300985809352975] [PMID]
15. Jensen HE, Krogh HV, Schonheyder H. Bovine mycotic abortion - a comparative study of diagnostic methods. Zentralbl Veterinarmed B. 1991; 38: 33-40. [DOI:10.1111/j.1439-0450.1991.tb00843.x] [PMID]
16. Thirion-Delalande C, Guillot J, Jensen HE. et al. Disseminated acute concomitant aspergillosis and mucormycosis in a pony. J Vet Med A. 2005; 52: 121-124. [DOI:10.1111/j.1439-0442.2005.00700.x] [PMID]
17. Guillot J, Collobert C, Jensen HE. et al. Two cases of equine mucormycosis caused by Absidia corymbifera. Equine Vet J. 2000; 32: 453-456. [DOI:10.2746/042516400777591039] [PMID]
18. Awadin W, Mosbah E, Youssef ES. et al. A case of subcutaneous destructive facial swelling in a dog caused by Mucor species. J Vet Sci Med Diag. 2015; 4; doi:10.4172/2325-9590.1000163 [DOI:10.4172/2325-9590.1000163]
19. Suzuta F, Kimura K, Urakawa R et al. Variations in the morphology of Rhizomucor pusillus in granulomatous lesions of a Magellanic penguin (Spheniscus magellanicus). J Vet Med Sci. 2015; 77: 1029-1031. [DOI:10.1292/jvms.14-0527] [PMID] [PMCID]
20. Kontoyianis DP, Vartivarian S, Anaissie EJ, Samonis G, Bodey GP, Rinaldi M. Infections due to Cunninghamella bertholletiae in patients with cancer: report of three cases and review. Clin Infect Dis. 1994; 18: 925-928. [DOI:10.1093/clinids/18.6.925] [PMID]
21. Tietz HJ, Brehmer D, Janisch W, Martin H. Incidence of endomycoses in the autopsy material of the Berlin Charite Hospital. Mycoses. 1998; 41(suppl 2): 81-85.
22. Mori T, Egashira M, Kawamata N. et al. Zygomycosis: two case reports and review of reported cases in the literature in Japan. Nippon Ishinkin Gakkai Zasshi. 2003; 44: 163-179. [DOI:10.3314/jjmm.44.163] [PMID]
23. Petrikkos G, Skiada A, Sambatakou H. et al. Mucormycosis: ten-year experience at a tertiary-care center in Greece. Eur J Clin Microbiol Infect Dis. 2003; 22: 753-756. [DOI:10.1007/s10096-003-1035-y] [PMID]
24. Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KV. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis. 2000; 30: 851-856. [DOI:10.1086/313803] [PMID]
25. Tedder M, Spratt JA, Anstadt MP, Hegde SS, Tedder SD, Lowe JE. Pulmonary mucormycosis: results of medical and surgical therapy. Ann Thorac Surg. 1994; 57: 1044-1150. [DOI:10.1016/0003-4975(94)90243-7]
26. Welk B, House AA, Ralph E, Tweedy E, Luke PP. Successful treatment of primary bilateral renal mucormycosis with bilateral nephrectomy. Urology. 2004; 64: 590. [DOI:10.1016/j.urology.2004.04.071] [PMID]
27. Reid VJ, Solnik DL, Daskalakis T, Sheka KP. Management of bronchovascular mucormycosis in a diabetic: a surgical success. Ann Thorac Surg. 2004; 78: 1449-1451. [DOI:10.1016/S0003-4975(03)01406-1]
28. Pavie J, Lafaurie M, Lacroix C. et al. Successful treatment of pulmonary mucormycosis in an allogenic bone-marrow transplant recipient with combined medical and surgical therapy. Scand J Infect Dis. 2004; 36: 767-769. [DOI:10.1080/00365540410021081a] [PMID]
29. Asai K, Suzuki K, Takahashi T, Ito Y, Kazui T, Kita Y. Pulmonary resection with chest wall removal and reconstruction for invasive pulmonary mucormycosis during antileukemia chemotherapy. Jpn J Thorac Cardiovasc Surg. 2003; 51: 163-16 [DOI:10.1007/s11748-003-0055-y] [PMID]
30. Walsh TJ, Hiemenz JW, Seibel NL. et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis. 1998; 26: 1383-1396. [DOI:10.1086/516353] [PMID]
31. Spellberg B, Fu Y, Edwards JE Jr, Ibrahim AS. Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice. Antimicrob Agents Chemother. 2005; 49: 830-832. [DOI:10.1128/AAC.49.2.830-832.2005] [PMID] [PMCID]
32. Barron MA, Lay M, Madinger NE. Surgery and treatment with high-dose liposomal amphotericin B for eradication of craniofacial zygomycosis in a patient with Hodgkin's disease who had undergone allogeneic hematopoietic stem cell transplantation. J Clin Microbiol. 2005; 43: 2012-2014. [DOI:10.1128/JCM.43.4.2012-2014.2005] [PMID] [PMCID]
33. Eisen DP, Robson J. Complete resolution of pulmonary Rhizopus oryzae infection with itraconazole treatment: more evidence of the utility of azoles for zygomycosis. Mycoses. 2004; 47: 159-162. [DOI:10.1111/j.1439-0507.2004.00959.x] [PMID]
34. Sun QN, Fothergill AW, McCarthy DI, Rinaldi MG, Graybill JR. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother. 2002; 46: 1581-1582. [DOI:10.1128/AAC.46.5.1581-1582.2002] [PMID] [PMCID]
35. Dannaoui E, Meletiadis J, Mouton JW, Meis JF, Verweij PE. In vitro susceptibilities of zygomycetes to conventional and new antifungals. J Antimicrob Chemother. 2003; 51: 45-52. [DOI:10.1093/jac/dkg020] [PMID]
36. Pfaller MA, Messer SA, Hollis RJ, Jones RN. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother. 2002; 46: 1032-1037. [DOI:10.1128/AAC.46.4.1032-1037.2002] [PMID] [PMCID]
37. Abzug MJ, Walsh TJ. Interferon-gamma and colony-stimulating factors as adjuvant therapy for refractory fungal infections in children. Pediatr Infect Dis J. 2004; 23: 769-773. [DOI:10.1097/01.inf.0000134314.65398.bf] [PMID]
38. Gil-Lamaignere C, Simitsopoulou M, Roilides E, Maloukou A, Winn RM, Walsh TJ. Interferon-gamma and granulocyte-macrophage colony-stimulating factor augment the activity of polymorphonuclear leukocytes against medically important Zygomycetes. J Infect Dis. 2005; 191: 1180-1187. [DOI:10.1086/428503] [PMID]
39. Huang C, Wang Y, Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223): 497-506. [DOI:10.1016/S0140-6736(20)30183-5]
40. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323(13): 1239-1242. [DOI:10.1001/jama.2020.2648] [PMID]
41. Zhu NA, Zhang D, Wang W. et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020; 382(8): 727-733. [DOI:10.1056/NEJMoa2001017] [PMID] [PMCID]
42. WHO. Listings of WHO's response to COVID-19. 2021; https://www. who.int/news/item/29-06-2020-covidtimeline
43. CCfSSa. Coronovirus COVID-19 global cases. 2021; https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740 fd40299423467b48e9ecf6
44. Mehta S, Pandey A. Rhino-orbital mucormycosis associated with COVID-19. Cureus. 2020; 12(9): e10726. [DOI:10.7759/cureus.10726]
45. Hughes S, Troise O, Donaldson H, Mughal N, Moore LSP. Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting. Clin Microbiol Infect. 2020; 26(10): 1395-1399. [DOI:10.1016/j.cmi.2020.06.025] [PMID] [PMCID]
46. Sharma S, Grover M, Bhargava S, Samdani S, Kataria T. Post coronavirus disease mucormycosis: a deadly addition to the pandemic spectrum. J Laryngol Otol. 2021; 1-6. [DOI:10.1017/S0022215121000992] [PMID] [PMCID]
47. Garg D, Muthu V, Sehgal IS. et al. Coronavirus disease (Covid-19) associated mucormycosis (CAM): case report and systematic review of literature. Mycopathol. 2021; 186(2): 289-298. [DOI:10.1007/s11046-021-00528-2] [PMID] [PMCID]
48. Song G, Liang G, Liu W. Fungal co-infections associated with global COVID-19 pandemic: a clinical and diagnostic perspective from China. Mycopathol. 2020; 185(4): 599-606. [DOI:10.1007/s11046-020-00462-9] [PMID] [PMCID]
49. Mekonnen ZK, Ashraf DC, Jankowski T. et al. Acute invasive rhinoorbital mucormycosis in a patient with COVID-19-associated acute respiratory distress syndrome. Ophthalmic Plast Reconstr Surg. 2021; 37(2): e40-e80. [DOI:10.1097/IOP.0000000000001889] [PMID] [PMCID]
50. Werthman-Ehrenreich A. Mucormycosis with orbital compartment syndrome in a patient with COVID-19. Am J Emerg Med. 2021; 42(264): e265-e264.e268. [DOI:10.1016/j.ajem.2020.09.032] [PMID] [PMCID]
51. Sen M, Lahane S, Lahane TP, Parekh R, Honavar SG. Mucor in a viral land: a tale of two pathogens. Indian J Ophthalmol. 2021; 69(2): 244-252. [DOI:10.4103/ijo.IJO_3774_20] [PMID] [PMCID]
52. Addie Diane D, McDonald Mike, Audhuy Stéphane, Burr Paul, Hollins Jonathan, Kovacic Rémi, Lutz Hans, Luxton Zoe, Mazar Shlomit, Meli Marina L. Quarantine protects Falkland Islands (Malvinas) cats from feline coronavirus infection. J Feline Med Surg. 2012; 14(2): 171-176. doi:10.1177/1098612X11429644. PMID 22314098. S2CID 4989860 [DOI:10.1177/1098612X11429644] [PMID]
53. Levy JK, Crawford PC, Lappin MR, Dubovi EJ, Levy MG, Alleman R, Tucker SJ, Clifford EL. Infectious diseases of dogs and cats on Isabela Island, Galapagos. J Vet Intern Med. 2008; 22(1): 60-65. doi:10.1111/j.1939-1676.2007.0034.x. PMC 7166416. PMID 18289290. S2CID 23423426. [DOI:10.1111/j.1939-1676.2007.0034.x] [PMID] [PMCID]
54. Rottier PJM, Nakamura Kazuya, Schellen Pepijn, Volders Haukeline, Haijema Bert Jan. Acquisition of Macrophage Tropism during the Pathogenesis of Feline Infectious Peritonitis is Determined by Mutations in the Feline Coronavirus Spike Protein. J Virol. 2005; 79(22): 14122-14130. doi: 10.1128/JVI.79.22.14122-14130.2005 PMC 1280227. PMID 16254347 [DOI:10.1128/JVI.79.22.14122-14130.2005] [PMID] [PMCID]
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |